TD Private Client Wealth’s Nektar Therapeutics NKTR Stock Holding History

TD Private Client Wealth’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13	Closed	-$1.09K	–	1268
2022 Q1	$1.09K	Buy	+13	New	+$1.92K	﹤0.01%	1208
2021 Q1	–	Sell	-1	Closed	-$136	–	1191
2020 Q4	$136	Hold	1	–	–	﹤0.01%	1141
2020 Q3	$133	Sell	1 -1	-50%	-$315	﹤0.01%	1108
2020 Q2	$648	Sell	2 -3	-60%	-$936	﹤0.01%	1000
2020 Q1	$1.28K	Sell	5 -14	-74%	-$4.33K	﹤0.01%	914
2019 Q4	$6.07K	Buy	+19	New	+$5.51K	﹤0.01%	800

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TD Private Client Wealth's NKTR Position: Q2 2022 in Review

TD Private Client Wealth sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 13 shares — an estimated $1.09K sold.

TD Private Client Wealth first reported a position in NKTR in Q4 2019 and held it in 6 quarters. The position peaked at $6.07K in Q4 2019. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

TD Private Client Wealth reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
TD Private Client Wealth sold 13 Nektar Therapeutics shares in Q2 2022, an estimated $1.09K.
TD Private Client Wealth first reported a position in Nektar Therapeutics in Q4 2019 and held it in 6 quarters.
TD Private Client Wealth's Nektar Therapeutics position peaked at $6.07K in Q4 2019.
227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on TD Private Client Wealth's 13F filing for Q2 2022, filed 16 Aug 2024.